Company Profile - Zynerba Pharmaceuticals Inc

Introduction

Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.